For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Tafamidis and the formulated version represents a significant change. These innovative therapies protect the transthyretin protein, halting its harmful build-up and reducing the impact of the illness. People are now seeing benefits in … Read More